SCHEDULE 13G/A 0001912606 XXXXXXXX LIVE 4 American Depository Shares 07/31/2025 0001075880 Kazia Therapeutics Limited 48669G105 Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW, C3 2000 Rule 13d-1(c) Alumni Capital LP DE 0.00 178591.00 0.00 178591.00 178591.00 Y 9.99 PN Alumni Capital GP LLC X1 0.00 178591.00 0.00 178591.00 178591.00 Y 9.99 OO Ashkan Mapar X1 0.00 178591.00 0.00 178591.00 178591.00 Y 9.99 IN Kazia Therapeutics Limited Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW, Australia, 2000 This statement is filed by Alumni Capital LP (the "Fund"), Alumni Capital GP LLC (the "General Partner"), and Ashkan Mapar (the "Controlling Person"). The foregoing are collectively referred to herein as the "Reporting Persons". The Fund holds, has the right to acquire, or has the obligation to acquire, securities of the Issuer. The General Partner serves as the general partner of the Fund. The Controlling person is the control person of the General Partner. The address for the principal business office of each of Alumni Capital LP, Alumni Capital GP LLC, and Ashkan Mapar is 601 Brickell Key Dr., Suite 700, Miami, FL 33131. Alumni Capital LP is a Delaware limited partnership. Alumni Capital GP LLC is a Delaware limited liability company. Ashkan Mapar is a citizen of the United States of America. Y Alumni Capital LP - 178,591* Alumni Capital GP LLC - 178,591* Ashkan Mapar - 178,591* *The American Depository Shares (the "ADSs") representing ordinary shares (the "Shares") of Kazia Therapeutics Limited (the "Issuer") reported herein represent ADSs are beneficially owned or that may be acquired by Alumni Capital LP (the "Fund") pursuant to (i) a Purchase Agreement dated April 19, 2024, between the Issuer and the Fund (the "Purchase Agreement"), (ii) warrants to purchase ADSs held by the Fund or to be issued to the Fund in consideration of the Fund's entering into the Purchase Agreement (the "Commitment Warrants"), (iii) warrants to purchase ADSs dated January 10, 2025 held by the Fund (the "Common Warrants"), and (iv) a Securities Purchase Agreement dated July 31, 2025, between the Issuer and the Fund (the "July Securities Purchase Agreement"). Under the Commitment Warrants and the Common Warrants, the Fund may acquire ADSs (or securities convertible into or exercisable for ADSs) in accordance with the respective terms and subject to the respective conditions and limitations contained therein. Furthermore, under the Purchase Agreement, at the Issuer's sole discretion, the Fund may be required to purchase ADSs, in accordance with the terms and subject to the conditions and limitations of the Purchase Agreement. One such limitation is that the Fund is prohibited from acquiring any ADSs, which, when aggregated with all other ADSs then beneficially owned by the Fund and its affiliates, would result in the beneficial ownership by the Fund and its affiliates to exceed 9.99% of the Shares outstanding (the "Ownership Limitation"). As such, the percent of class reported herein is giving effect to the Ownership Limitation and is based upon the Issuer's representation in the prospectus supplement of the Issuer filed on July 25, 2025 pursuant to Rule 424(b)(5)) that there were 1,609,108 ADSs (assuming all holders of Shares held ADSs) outstanding as of July 25, 2025 plus the approximate total number of Shares that the Reporting Persons may acquire at the direction of the Issuer (subject to the Ownership Limitation) in accordance with Rule 13d-3(d)(1)(i) under the Act. For the sake of clarity, the Fund owns 28,409 ADSs as of the date of the filing and is electing to file this Schedule 13G solely to the extent that, for the purposes of Section 240.13d-3, the Reporting Persons are deemed to beneficially own the ADSs pursuant to the Purchase Agreement, the Commitment Warrants, and the Common Warrants. The filing of this report shall not be deemed an admission, for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the ADSs reported herein except to the extent of such Reporting Person's pecuniary interest, if any, therein. Alumni Capital LP - 9.99% Alumni Capital GP LLC - 9.99% Ashkan Mapar - 9.99% Alumni Capital LP - 0 Alumni Capital GP LLC - 0 Ashkan Mapar - 0 Alumni Capital LP - 178,591* Alumni Capital GP LLC - 178,591* Ashkan Mapar - 178,591* Alumni Capital LP - 0 Alumni Capital GP LLC - 0 Ashkan Mapar - 0 Alumni Capital LP - 178,591* Alumni Capital GP LLC - 178,591* Ashkan Mapar - 178,591* Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. A. Agreement of Joint Filing Alumni Capital LP /s/ Ashkan Mapar 09/11/2025 Alumni Capital GP LLC /s/ Ashkan Mapar 09/11/2025 Ashkan Mapar /s/ Ashkan Mapar 09/11/2025